Molecular Cytogenetics Market - Global Forecast to 2030
商品番号 : SMB-50586
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年10月 |
| ページ数 | 377 |
| 図表数 | 462 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
分子細胞遺伝学市場 – 製品（キット、試薬、プローブ、機器、ソフトウェア、サービス）、技術（FISH、CISH、比較ゲノムハイブリダイゼーション（アレイベース、標準）、アプリケーション（がん、個別化医療） – 2030年までの世界予測
分子細胞遺伝学市場は、2025年の10億2,000万米ドルから2030年には14億3,000万米ドルに達し、予測期間中は年平均成長率（CAGR）7.1%で成長すると予測されています。市場の成長を牽引しているのは、主に高齢者層におけるがんや遺伝性疾患の罹患率の上昇です。正確な診断と疾患管理のための分子細胞遺伝学検査の適用拡大も重要な役割を果たしています。さらに、標的療法の出現と個別化医療への統合も、市場の成長をさらに促進しています。しかしながら、高度な分子細胞遺伝学技術に伴う高額な費用と熟練した専門家の必要性は、依然として市場拡大の大きな障壁となっています。
この調査レポートでは、分子細胞遺伝学市場を製品とサービス（キットと試薬［検査キット、プローブ、蛍光親和性試薬、その他のキットと試薬］、機器、消耗品、ソフトウェアとサービス）、技術（比較ゲノムハイブリダイゼーション［アレイベースの比較ゲノムハイブリダイゼーション、標準的な比較ゲノムハイブリダイゼーション］、蛍光in situハイブリダイゼーション、発色in situハイブリダイゼーション、その他の技術）、アプリケーション（がん、遺伝性疾患、個別化医療、その他のアプリケーション）、エンドユーザー（臨床および研究ラボ、学術および研究機関、製薬およびバイオテクノロジー企業、その他のエンドユーザー）、および地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ）別に分類しています。
本レポートは、分子細胞遺伝学市場の成長に影響を与える主要な要因（推進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーの包括的な分析により、事業概要、製品ポートフォリオ、主要戦略、新製品の発売、買収、そして分子細胞遺伝学市場に関連する最近の動向に関する洞察を提供しています。また、本レポートには、分子細胞遺伝学業界エコシステムにおける新興スタートアップ企業の競合分析も含まれています。
本レポートは、市場全体とそのサブセグメントの収益予測を提供することで、市場リーダーと新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、自社の効果的なポジショニングと適切な市場開拓戦略の策定に役立つ洞察を得るのに役立ちます。本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供することを可能にします。
本レポートでは、以下の点について洞察を提供しています。
- 市場の成長に影響を与える主要な推進要因（がんおよび遺伝性疾患の発生率の増加、がん標的治療への注目度の高まり、高齢化の急速な進展とそれに伴う慢性疾患の有病率の増加、臨床病理学的検査における分子細胞遺伝学の普及拡大）、制約要因（高度な機器の高コストと不利な償還シナリオ）、機会（未開拓の新興市場）、課題（FISH法からアレイベース技術への移行）の分析
- 製品開発／イノベーション：新発売製品に関する詳細な洞察と分子細胞遺伝学市場の技術評価
- 市場開発：収益性の高い市場に関する包括的な情報と、様々な地域における市場分析
- 市場多様化：分子細胞遺伝学市場における新製品、未開拓地域、最近の動向、投資に関する網羅的な情報
- 競合評価：分子細胞遺伝学市場において製品・サービスを提供している主要企業（F. Hoffman-La Roche Ltd（スイス）、Danaher（米国）、Agilent Technologies, Inc.（米国）、Abbott（米国）、Thermo Fisher Scientific Inc.（米国）、Illumina, Inc.（米国）など）の市場シェア、成長戦略、製品ラインナップを詳細に評価します。その他、分子細胞遺伝学市場において製品・サービスを提供している企業としては、Applied Spectral Imaging Inc.（米国）、Biomodal（英国）、Biocare Medical, LLC（米国）、OncoDNA（ベルギー）などが挙げられます。
Report Description
The molecular cytogenetics market is expected to reach USD 1.43 billion in 2030 from USD 1.02 billion in 2025, at a CAGR of 7.1% during the forecast period. The market is driven by a rising prevalence of cancer and genetic disorders, mainly among older adults. The growing application of molecular cytogenetic tests for accurate diagnosis and disease management also plays a crucial role. Furthermore, the emergence of targeted therapies and their integration into personalized medicine are further driving market growth. Nonetheless, the high expenses associated with advanced molecular cytogenetic techniques and the requirement for skilled professionals continue to be major barriers to market expansion.
“Testing kits segment is expected to grow at the highest CAGR during the forecast period”
The testing kits segment is growing at the highest CAGR in the molecular cytogenetics market due to its ease of use, reproducibility, and ability to deliver rapid, accurate results. These kits, including CGH arrays and FISH probe panels, enable standardized detection of chromosomal abnormalities and genetic variations across clinical and research laboratories. By leveraging pre-validated assays and integrated analysis tools, testing kits offer reliable, high-throughput solutions that support oncology, prenatal testing, and genetic disorder diagnostics. Their convenience, accuracy, and scalability make them essential for efficient cytogenetic testing, driving their strong adoption in the market.
“Cancer application segment holds the largest share of the market”
The cancer applications segment accounts for the largest share of the molecular cytogenetics market. This growth is primarily driven by the rising incidence of cancer worldwide, particularly among the aging population, which is more susceptible to malignancies. Genetic changes and chromosomal abnormalities are major contributors to tumor development, increasing the demand for molecular cytogenetic testing in oncology. Techniques such as fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH) enable the precise detection of these abnormalities, facilitating accurate diagnosis, classification of tumor types, and monitoring of disease progression. Furthermore, increasing investments in cancer research, improvements in healthcare infrastructure, and growing awareness of the benefits of early detection and genetic profiling are contributing to the robust growth of this segment across clinical and research settings globally.
“US is expected to grow at the highest CAGR during the forecast period”
The US is experiencing the highest growth rate in the molecular cytogenetics market due to several factors. The presence of leading cytogenetics companies, advanced research infrastructure, and a large patient base are major drivers of market growth in the country. Additionally, rising adoption of molecular cytogenetic testing in oncology, prenatal screening, and genetic disorder diagnostics is fueling demand. Supportive healthcare regulations, increased funding for genomic research, and the growing focus on precision medicine further contribute to the expansion of the molecular cytogenetics market in the US.
Additionally, the widespread adoption of molecular cytogenetic techniques, such as FISH and CGH, for the accurate detection of chromosomal abnormalities has further supported the growth of molecular cytogenetics. Extensive government and private funding for biomedical research and oncology accelerates innovation and the deployment of cutting-edge testing platforms. The region’s stringent regulatory framework ensures product quality and reliability, further strengthening trust in molecular cytogenetic solutions and solidifying North America’s dominant position globally.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tier 1 – 25%, Tier 2 – 35%, and Tier 3 – 40%
- By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25%
- By Region: North America – 35%, Europe – 25%, Asia Pacific – 15%, Latin America – 10%, the Middle East – 10%, and Africa – 5%
Hoffmann-La Roche Ltd. (Switzerland), Danaher (US), Agilent Technologies, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Revvity (US), PacBio (US), Bio-Rad Laboratories, Inc. (US), Bio-Techne (US), GeneDx, LLC (US), Insight Molecular Diagnostics Inc. (US), BioView (Israel), Oxford Gene Technology IP Limited (UK), Applied Spectral Imaging, Inc. (US), CytoTest Inc. (US), KROMATID (US), Genial Genetic Solutions Ltd. (UK), Cytognomix Inc. (Canada), MetaSystems (Germany), SciGene Corporation (US), Biomodal (UK), Biocare Medical, LLC (US), BioDot (US), and OncoDNA (Belgium) are some of the key companies offering molecular cytogenetics products.
Research Coverage
This research report categorizes the molecular cytogenetics market by product & service (kits & reagents [testing kits, probes, fluorescent affinity reagents, other kits & reagents], instruments, consumables, software & services), technique (comparative genomic hybridization [array-based comparative genomic hybridization, standard comparative genomic hybridization], fluorescence in-situ hybridization, chromogenic in-situ hybridization, other techniques), application (cancer, genetic disorders, personalized medicine and other applications), end user (clinical & research laboratories, academic & research institutes, pharmaceutical & biotechnology companies, other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa).
The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the molecular cytogenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the molecular cytogenetics market. This report also includes a competitive analysis of emerging startups in the molecular cytogenetics industry ecosystem.
Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market’s pulse and offer information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (increasing incidence of cancer and genetic disorders, growing focus on targeted cancer treatment, rapid growth in aging population and subsequent increase in prevalence of chronic diseases, and increasing penetration of molecular cytogenetics in clinical pathological testing), restraints (high cost of advanced instruments and unfavourable reimbursement scenario), opportunities (untapped emerging markets), and challenges (transition from FISH to array-based techniques) influencing the market growth
- Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the molecular cytogenetics market
- Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular cytogenetics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including F. Hoffman-La Roche Ltd (Switzerland), Danaher (US), Agilent Technologies, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), among others offering products and services for molecular cytogenetics market. Other companies include Applied Spectral Imaging Inc. (US), Biomodal (UK), Biocare Medical, LLC (US), OncoDNA (Belgium), among others, for the molecular cytogenetics market
Table of Contents
1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.3 STUDY SCOPE 35
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 35
1.3.2 INCLUSIONS & EXCLUSIONS 36
1.3.3 YEARS CONSIDERED 36
1.3.4 CURRENCY CONSIDERED 36
1.4 STAKEHOLDERS 37
1.5 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
2.1.1 SECONDARY DATA 39
2.1.1.1 Key sources of secondary data 39
2.1.1.2 Key objectives of secondary research 39
2.1.2 PRIMARY DATA 40
2.1.2.1 Breakdown of primaries 40
2.1.2.2 Key objectives of primary research 40
2.2 MARKET SIZE ESTIMATION 41
2.2.1 GLOBAL MOLECULAR CYTOGENETICS MARKET SIZE ESTIMATION, 2024 41
2.2.1.1 Revenue share analysis (bottom-up approach) 41
2.2.1.2 Secondary data & primary interviews 43
2.2.1.2.1 Insights of primary experts 44
2.2.1.3 MnM repository analysis 44
2.2.2 SEGMENTAL MARKET ASSESSMENT: TOP-DOWN APPROACH 45
2.3 MARKET GROWTH RATE PROJECTION 46
2.4 DATA TRIANGULATION 48
2.5 STUDY ASSUMPTIONS 49
2.6 RESEARCH LIMITATIONS 50
2.7 RISK ANALYSIS 50
3 EXECUTIVE SUMMARY 51
3.1 KEY INSIGHTS & MARKET HIGHLIGHTS 51
3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS 55
3.3 DISRUPTIVE TRENDS SHAPING MOLECULAR CYTOGENETICS MARKET 56
3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 56
3.5 GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 57
4 PREMIUM INSIGHTS 58
4.1 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION AND COUNTRY 58
4.2 MOLECULAR CYTOGENETICS MARKET SHARE, BY END USER, 2024 59
4.3 MOLECULAR CYTOGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 60
4.5 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS 62
4.6 VC/PRIVATE EQUITY INVESTMENT TRENDS 62
5 MARKET OVERVIEW 64
5.1 INTRODUCTION 64
5.2 MARKET DYNAMICS 64
5.2.1 DRIVERS 65
5.2.1.1 Advancement and adoption of high-resolution techniques 65
5.2.1.2 Growing focus on targeted cancer treatment 66
5.2.1.3 Increasing penetration of molecular cytogenetics in clinical pathological testing 67
5.2.2 RESTRAINTS 68
5.2.2.1 High cost of advanced instruments 68
5.2.2.2 Unfavorable reimbursement scenario for advanced diagnostic tests 68
5.2.3 OPPORTUNITIES 69
5.2.3.1 Untapped emerging markets 69
5.2.4 CHALLENGES 69
5.2.4.1 Transition from FISH to array-based molecular cytogenetic techniques in diagnostic and research communities 69
5.3 UNMET NEEDS & WHITE SPACES 70
6 INDUSTRY TRENDS 71
6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 71
6.2 CASE STUDY ANALYSIS 71
6.2.1 MOSAIC TETRASOMY 9P TO BE DETECTED BY CNV-SEQ IN PRENATAL DIAGNOSIS 71
6.2.2 PRENATAL DETECTION OF 15Q21.3 AND 16P11.2 MICRODUPLICATION SYNDROMES USING CNV-SEQ AND WES 72
6.2.3 INTEGRATED CNV-SEQ AND KARYOTYPING IN LARGE PRENATAL COHORT FOR CHROMOSOMAL ABNORMALITY DETECTION 72
6.3 TECHNOLOGY ANALYSIS 72
6.3.1 KEY TECHNOLOGIES 73
6.3.1.1 Optical genome mapping 73
6.3.1.2 Next-generation sequencing 73
6.3.2 COMPLEMENTARY TECHNOLOGIES 73
6.3.2.1 CRISPR-based editing 73
6.4 PRICING ANALYSIS 74
6.4.1 AVERAGE SELLING PRICE TREND OF MOLECULAR CYTOGENETIC PRODUCTS, BY KEY PLAYER, 2022–2024 74
6.4.2 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2022–2024 76
6.5 PATENT ANALYSIS 79
6.5.1 METHODOLOGY 79
6.5.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 79
6.5.3 LIST OF KEY PATENTS 81
6.6 TRADE ANALYSIS 82
6.6.1 IMPORT DATA FOR HS CODE 3822.00, 2020–2024 82
6.6.2 EXPORT DATA FOR HS CODE 3822.00, 2020–2024 83
6.7 VALUE CHAIN ANALYSIS 84
6.8 ECOSYSTEM ANALYSIS 85
6.8.1 ROLE IN ECOSYSTEM 88
6.8.2 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS 88
6.9 PORTER’S FIVE FORCES ANALYSIS 89
6.9.1 INTENSITY OF COMPETITIVE RIVALRY 90
6.9.2 BARGAINING POWER OF SUPPLIERS 91
6.9.3 BARGAINING POWER OF BUYERS 91
6.9.4 THREAT OF SUBSTITUTES 91
6.9.5 THREAT OF NEW ENTRANTS 91
6.10 KEY STAKEHOLDERS & BUYING CRITERIA 92
6.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 92
6.10.2 KEY BUYING CRITERIA 93
6.11 TARIFF & REGULATORY ANALYSIS 94
6.11.1 TARIFF DATA FOR HS CODES 9027.50.80 AND 3822.00 94
6.11.1.1 US 94
6.11.1.2 European Union 94
6.11.1.3 Asia Pacific 94
6.11.2 REGULATORY LANDSCAPE 95
6.11.2.1 North America 95
6.11.2.1.1 US 95
6.11.2.1.2 Canada 97
6.11.2.2 Europe 97
6.11.2.3 Asia Pacific 99
6.11.2.3.1 Japan 99
6.11.2.3.2 China 100
6.11.2.3.3 India 100
6.11.2.4 Latin America 101
6.11.2.4.1 Brazil 101
6.11.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
6.11.4 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 104
6.12 KEY CONFERENCES & EVENTS, 2025–2026 105
6.13 INVESTMENT & FUNDING SCENARIO 106
6.14 IMPACT OF AI/GEN AI ON MOLECULAR CYTOGENETICS MARKET 107
6.15 IMPACT OF 2025 US TARIFF ON MOLECULAR CYTOGENETICS MARKET 109
6.15.1 INTRODUCTION 109
6.15.2 KEY TARIFF RATES 109
6.15.3 PRICE IMPACT ANALYSIS 111
6.15.4 KEY IMPACT ON COUNTRIES/REGIONS 112
6.15.4.1 North America 112
6.15.4.1.1 US 112
6.15.4.2 Europe 113
6.15.4.3 Asia Pacific 113
6.15.5 IMPACT OF END-USE INDUSTRIES 114
6.15.5.1 Clinical & diagnostic laboratories 114
6.15.5.2 Academic & research institutes 114
6.15.5.3 Pharmaceutical & biotechnology companies 114
7 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE 115
7.1 INTRODUCTION 116
7.2 KITS & REAGENTS 116
7.2.1 TESTING KITS 120
7.2.1.1 Standardized and integrated kit workflows to propel market growth 120
7.2.2 PROBES 124
7.2.2.1 Advances in oligonucleotide probe chemistry, multiplexing, and regulatory-driven product modernization to boost market 124
7.2.3 FLUORESCENT AFFINITY REAGENTS 127
7.2.3.1 Improved fluorochrome chemistry and pre-validated conjugates paired with advanced spectral imaging to drive growth 127
7.2.4 OTHER KITS & REAGENTS 131
7.3 CONSUMABLES 134
7.3.1 STANDARDIZATION AND EXPANDING CLINICAL APPLICATIONS TO PROMOTE MARKET GROWTH 134
7.4 INSTRUMENTS 138
7.4.1 AUTOMATION, AI-ENABLED IMAGING, AND INTEGRATED PLATFORMS TO DRIVE MARKET 138
7.5 SOFTWARE & SERVICES 141
7.5.1 AI INTEGRATION, WORKFLOW STANDARDIZATION, AND CLOUD-ENABLED DATA MANAGEMENT TO DRIVE MARKET 141
8 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE 145
8.1 INTRODUCTION 146
8.2 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 146
8.2.1 INTEGRATION OF FISH AND ADVANCED IMAGING TECHNOLOGIES TO DRIVE GROWTH 146
8.3 ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH) 150
8.3.1 BETTER CLINICAL ACCEPTANCE AND IMPROVED TECHNOLOGICAL INTEGRATION TO PROPEL MARKET GROWTH 150
8.4 CHROMOGENIC IN SITU HYBRIDIZATION (CISH) 153
8.4.1 ENHANCED PROBE TECHNOLOGY AND BETTER WORKFLOW AUTOMATION TO BOOST MARKET GROWTH 153
8.5 OTHER TECHNIQUES 157
9 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION 161
9.1 INTRODUCTION 162
9.2 GENETIC DISORDERS 162
9.2.1 EXPANDED CLINICAL GUIDELINES AND IMPROVED CMA/FISH TECHNOLOGIES TO PROPEL MARKET GROWTH 162
9.3 CANCER 166
9.3.1 RISING CANCER RESEARCH AND INCREASING USE OF AUTOMATED CYTOGENETIC PLATFORMS TO DRIVE MARKET 166
9.4 PERSONALIZED MEDICINE 169
9.4.1 STRATEGIC COLLABORATIONS AND BIOMARKER-DRIVEN CYTOGENETIC TESTING TO ACCELERATE MARKET GROWTH 169
9.5 OTHER APPLICATIONS 173
10 MOLECULAR CYTOGENETICS MARKET, BY END USER 177
10.1 INTRODUCTION 178
10.2 CLINICAL & DIAGNOSTIC LABORATORIES 178
10.2.1 INVESTMENT IN AUTOMATION AND INDUSTRY PARTNERSHIPS TO DRIVE MARKET GROWTH 178
10.3 ACADEMIC & RESEARCH INSTITUTES 182
10.3.1 STRATEGIC ACADEMIA–INDUSTRY COLLABORATIONS TO AUGMENT MARKET GROWTH 182
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 185
10.4.1 STRATEGIC ACQUISITIONS AND PRECISION MEDICINE INTEGRATION TO FUEL MARKET GROWTH 185
10.5 OTHER END USERS 189
11 MOLECULAR CYTOGENETICS MARKET, BY REGION 193
11.1 INTRODUCTION 194
11.2 NORTH AMERICA 194
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 194
11.2.2 US 199
11.2.2.1 US to dominate North American molecular cytogenetics market during study period 199
11.2.3 CANADA 202
11.2.3.1 Increasing cancer burden and expanding application of cytogenetics technology in oncology to drive market 202
11.3 EUROPE 205
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 205
11.3.2 GERMANY 210
11.3.2.1 Dynamic convergence of research excellence, clinical adoption, and industry collaboration to augment market growth 210
11.3.3 UK 213
11.3.3.1 Strong governmental support for genomics research and advanced healthcare infrastructure to aid market growth 213
11.3.4 FRANCE 215
11.3.4.1 Increasing government investment in pharmaceutical industry to support market growth 215
11.3.5 ITALY 218
11.3.5.1 Rising research activities in pharma R&D to boost market growth 218
11.3.6 SPAIN 221
11.3.6.1 Well-established network of research centers and universities to boost clinical and diagnostic research 221
11.3.7 REST OF EUROPE 224
11.4 ASIA PACIFIC 227
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 227
11.4.2 CHINA 232
11.4.2.1 Development of advanced healthcare infrastructure and government support for genomics research to propel growth 232
11.4.3 JAPAN 235
11.4.3.1 Technological adoption and increased clinical programs to favor market growth 235
11.4.4 INDIA 238
11.4.4.1 Rising awareness of cancer and genetic disorders to support market growth 238
11.4.5 AUSTRALIA 241
11.4.5.1 Progressive translational research, advanced diagnostic integration, and cross-institutional collaborations to fuel growth 241
11.4.6 SOUTH KOREA 244
11.4.6.1 Technological innovation and high demand for precision medicines to aid market growth 244
11.4.7 REST OF ASIA PACIFIC 247
11.5 LATIN AMERICA 250
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 250
11.5.2 BRAZIL 254
11.5.2.1 Increased number of public-private collaborations to focus on strategic market expansions 254
11.5.3 MEXICO 257
11.5.3.1 Strengthening genomic infrastructure and technology integration to support market growth 257
11.5.4 REST OF LATIN AMERICA 260
11.6 MIDDLE EAST 263
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 263
11.6.2 GCC COUNTRIES 267
11.6.2.1 Kingdom of Saudi Arabia 270
11.6.2.1.1 Growing healthcare expenditure to boost market growth 270
11.6.2.2 UAE 273
11.6.2.2.1 Rising government support and incorporation of ISH technologies by hospitals to aid market growth 273
11.6.2.3 Rest of GCC countries 276
11.6.3 REST OF MIDDLE EAST 279
11.7 AFRICA 282
11.7.1 GROWING MARKET FOR PHARMACEUTICALS AND INCREASING DEMAND FOR GENETIC TESTING TO PROPEL GROWTH 282
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 282
12 COMPETITIVE LANDSCAPE 286
12.1 INTRODUCTION 286
12.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 286
12.3 REVENUE ANALYSIS, 2020–2024 289
12.4 MARKET SHARE ANALYSIS, 2024 290
12.5 COMPANY VALUATION & FINANCIAL METRICS 292
12.5.1 FINANCIAL METRICS 292
12.5.2 COMPANY VALUATION 292
12.6 BRAND/PRODUCT COMPARISON 293
12.6.1 F. HOFFMANN-LA ROCHE LTD. 293
12.6.2 DANAHER CORPORATION 294
12.6.3 AGILENT TECHNOLOGIES, INC. 294
12.6.4 ABBOTT 294
12.6.5 THERMO FISHER SCIENTIFIC INC. 294
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 294
12.7.1 STARS 294
12.7.2 EMERGING LEADERS 294
12.7.3 PERVASIVE PLAYERS 295
12.7.4 PARTICIPANTS 295
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 296
12.7.5.1 Company footprint 296
12.7.5.2 Region footprint 296
12.7.5.3 Product & service footprint 297
12.7.5.4 Technique footprint 298
12.7.5.5 Application footprint 298
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 299
12.8.1 PROGRESSIVE COMPANIES 299
12.8.2 RESPONSIVE COMPANIES 299
12.8.3 DYNAMIC COMPANIES 299
12.8.4 STARTING BLOCKS 299
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 301
12.8.5.1 Detailed list of key startups/SMEs 301
12.8.5.2 Competitive benchmarking of key startups/SMEs 302
12.9 COMPETITIVE SCENARIO 303
12.9.1 PRODUCT LAUNCHES & APPROVALS 303
12.9.2 DEALS 304
12.9.3 EXPANSIONS 305
12.9.4 OTHER DEVELOPMENTS 305
13 COMPANY PROFILES 306
13.1 KEY PLAYERS 306
13.1.1 F. HOFFMANN-LA ROCHE LTD. 306
13.1.1.1 Business overview 306
13.1.1.2 Products/Services offered 307
13.1.1.3 Recent developments 309
13.1.1.3.1 Product launches & approvals 309
13.1.1.4 MnM view 310
13.1.1.4.1 Key strengths 310
13.1.1.4.2 Strategic choices 310
13.1.1.4.3 Weaknesses & competitive threats 310
13.1.2 DANAHER CORPORATION 311
13.1.2.1 Business overview 311
13.1.2.2 Products/Services offered 312
13.1.2.3 Recent developments 314
13.1.2.3.1 Product launches 314
13.1.2.3.2 Deals 315
13.1.2.4 MnM view 315
13.1.2.4.1 Key strengths 315
13.1.2.4.2 Strategic choices 315
13.1.2.4.3 Weaknesses & competitive threats 316
13.1.3 AGILENT TECHNOLOGIES, INC. 317
13.1.3.1 Business overview 317
13.1.3.2 Products/Services offered 318
13.1.3.3 Recent developments 320
13.1.3.3.1 Product launches 320
13.1.3.3.2 Deals 321
13.1.3.3.3 Other developments 321
13.1.3.4 MnM view 322
13.1.3.4.1 Key strengths 322
13.1.3.4.2 Strategic choices 322
13.1.3.4.3 Weaknesses & competitive threats 322
13.1.4 ABBOTT 323
13.1.4.1 Business overview 323
13.1.4.2 Products/Services offered 324
13.1.4.3 MnM view 325
13.1.4.3.1 Key strengths 325
13.1.4.3.2 Strategic choices 325
13.1.4.3.3 Weaknesses & competitive threats 325
13.1.5 THERMO FISHER SCIENTIFIC INC. 326
13.1.5.1 Business overview 326
13.1.5.2 Products/Services offered 327
13.1.5.3 Recent developments 329
13.1.5.3.1 Product launches 329
13.1.5.3.2 Deals 329
13.1.5.4 MnM view 330
13.1.5.4.1 Key strengths 330
13.1.5.4.2 Strategic choices 330
13.1.5.4.3 Weaknesses & competitive threats 330
13.1.6 ILLUMINA, INC. 331
13.1.6.1 Business overview 331
13.1.6.2 Products/Services offered 332
13.1.6.3 Recent developments 333
13.1.6.3.1 Deals 333
13.1.6.3.2 Expansions 334
13.1.7 REVVITY 335
13.1.7.1 Business overview 335
13.1.7.2 Products/Services offered 336
13.1.7.3 Recent developments 337
13.1.7.3.1 Product launches 337
13.1.7.3.2 Deals 338
13.1.8 PACBIO 339
13.1.8.1 Business overview 339
13.1.8.2 Products/Services offered 340
13.1.8.3 Recent developments 341
13.1.8.3.1 Deals 341
13.1.8.3.2 Expansions 342
13.1.9 BIO-RAD LABORATORIES, INC. 343
13.1.9.1 Business overview 343
13.1.9.2 Products/Services offered 344
13.1.10 BIO-TECHNE 347
13.1.10.1 Business overview 347
13.1.10.2 Products/Services offered 348
13.1.10.3 Recent developments 349
13.1.10.3.1 Product launches 349
13.1.10.3.2 Deals 350
13.1.11 GENE DX, LLC 351
13.1.11.1 Business overview 351
13.1.11.2 Products/Services offered 352
13.1.11.3 Recent developments 352
13.1.11.3.1 Deals 352
13.1.12 INSIGHT MOLECULAR DIAGNOSTICS INC. 353
13.1.12.1 Business overview 353
13.1.12.2 Products/Services offered 354
13.1.13 BIOVIEW 355
13.1.13.1 Business overview 355
13.1.13.2 Products/Services offered 355
13.2 OTHER PLAYERS 357
13.2.1 OXFORD GENE TECHNOLOGY IP LIMITED 357
13.2.2 APPLIED SPECTRAL IMAGING 358
13.2.3 CYTOTEST INC. 359
13.2.4 KROMATID 360
13.2.5 GENIAL GENETIC SOLUTIONS LTD. 361
13.2.6 CYTOGNOMIX INC. 362
13.2.7 METASYSTEMS 363
13.2.8 SCIGENE CORPORATION 364
13.2.9 BIOMODAL 365
13.2.10 BIOCARE MEDICAL, LLC 366
13.2.11 BIODOT 367
13.2.12 ONCODNA 368
14 APPENDIX 369
14.1 DISCUSSION GUIDE 369
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 373
14.3 CUSTOMIZATION OPTIONS 375
14.4 RELATED REPORTS 375
14.5 AUTHOR DETAILS 376
LIST OF TABLES
TABLE 1 MOLECULAR CYTOGENETICS MARKET: INCLUSIONS & EXCLUSIONS 36
TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 47
TABLE 3 MOLECULAR CYTOGENETICS MARKET: RISK ANALYSIS 50
TABLE 4 IMPACT ANALYSIS OF MOLECULAR CYTOGENETICS MARKET DYNAMICS 65
TABLE 5 AVERAGE SELLING PRICE TREND OF MOLECULAR CYTOGENETIC PRODUCTS,
BY KEY PLAYER, 2022–2024 (USD) 74
TABLE 6 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION,
2022–2024 (USD) 76
TABLE 7 AVERAGE SELLING PRICE TREND OF KITS, BY REGION, 2022–2024 (USD) 77
TABLE 8 AVERAGE SELLING PRICE TREND OF REAGENTS, BY REGION, 2022–2024 (USD) 77
TABLE 9 NUMBER OF PATENTS FILED IN MOLECULAR CYTOGENETICS MARKET,
BY DOCUMENT TYPE, 2014–2024 79
TABLE 10 LIST OF KEY PATENTS IN MOLECULAR CYTOGENETICS MARKET, 2023–2025 81
TABLE 11 IMPORT DATA FOR HS CODE 3822.00, BY COUNTRY,
2020–2024 (USD THOUSAND) 82
TABLE 12 EXPORT DATA FOR HS CODE 3822.00, BY COUNTRY,
2020–2024 (USD THOUSAND) 83
TABLE 13 MOLECULAR CYTOGENETICS MARKET: ROLE IN ECOSYSTEM 88
TABLE 14 MOLECULAR CYTOGENETICS MARKET: PORTER’S FIVE FORCES 89
TABLE 15 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS,
BY PRODUCT & SERVICE 92
TABLE 16 KEY BUYING CRITERIA, BY END USER 93
TABLE 17 TARIFF DATA FOR HS CODES 9027.50.80 AND 3822.00 95
TABLE 18 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 95
TABLE 19 EUROPE: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 97
TABLE 20 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS 99
TABLE 21 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 100
TABLE 22 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 100
TABLE 23 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
TABLE 24 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
TABLE 25 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104
TABLE 27 LIST OF KEY CONFERENCES & EVENTS IN MOLECULAR CYTOGENETICS MARKET, JANUARY 2025–DECEMBER 2026 105
TABLE 28 KEY PLAYERS IMPLEMENTING AI/GEN AI IN MOLECULAR CYTOGENETICS MARKET 108
TABLE 29 US ADJUSTED RECIPROCAL TARIFF RATES 109
TABLE 30 EXPORTS AND IMPORTS, BY REGION 110
TABLE 31 KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO MOLECULAR CYTOGENETICS 111
TABLE 32 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 112
TABLE 33 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 116
TABLE 34 MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 117
TABLE 35 MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY REGION,
2023–2030 (USD MILLION) 117
TABLE 36 NORTH AMERICA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 37 EUROPE: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 38 ASIA PACIFIC: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 39 LATIN AMERICA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 40 MIDDLE EAST: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET,
BY REGION, 2023–2030 (USD MILLION) 120
TABLE 41 GCC COUNTRIES: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 42 MOLECULAR CYTOGENETICS TESTING KITS MARKET, BY REGION,
2023–2030 (USD MILLION) 121
TABLE 43 NORTH AMERICA: MOLECULAR CYTOGENETICS TESTING KITS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 44 EUROPE: MOLECULAR CYTOGENETICS TESTING KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 45 ASIA PACIFIC: MOLECULAR CYTOGENETICS TESTING KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 46 LATIN AMERICA: MOLECULAR CYTOGENETICS TESTING KITS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 47 MIDDLE EAST: MOLECULAR CYTOGENETICS TESTING KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 123
TABLE 48 GCC COUNTRIES: MOLECULAR CYTOGENETICS TESTING KITS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 49 MOLECULAR CYTOGENETICS PROBES MARKET, BY REGION,
2023–2030 (USD MILLION) 124
TABLE 50 NORTH AMERICA: MOLECULAR CYTOGENETICS PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 51 EUROPE: MOLECULAR CYTOGENETICS PROBES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 125
TABLE 52 ASIA PACIFIC: MOLECULAR CYTOGENETICS PROBES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 126
TABLE 53 LATIN AMERICA: MOLECULAR CYTOGENETICS PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 54 MIDDLE EAST: MOLECULAR CYTOGENETICS PROBES MARKET, BY REGION,
2023–2030 (USD MILLION) 127
TABLE 55 GCC COUNTRIES: MOLECULAR CYTOGENETICS PROBES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 56 MOLECULAR CYTOGENETICS FLUORESCENT AFFINITY REAGENTS MARKET,
BY REGION, 2023–2030 (USD MILLION) 128
TABLE 57 NORTH AMERICA: MOLECULAR CYTOGENETICS FLUORESCENT AFFINITY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 58 EUROPE: MOLECULAR CYTOGENETICS FLUORESCENT AFFINITY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 59 ASIA PACIFIC: MOLECULAR CYTOGENETICS FLUORESCENT AFFINITY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 60 LATIN AMERICA: MOLECULAR CYTOGENETICS FLUORESCENT AFFINITY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 61 MIDDLE EAST: MOLECULAR CYTOGENETICS FLUORESCENT AFFINITY REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 130
TABLE 62 GCC COUNTRIES: MOLECULAR CYTOGENETICS FLUORESCENT AFFINITY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 63 OTHER MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 131
TABLE 64 NORTH AMERICA: OTHER MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 65 EUROPE: OTHER MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 66 ASIA PACIFIC: OTHER MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 67 LATIN AMERICA: OTHER MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 68 MIDDLE EAST: OTHER MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET,
BY REGION, 2023–2030 (USD MILLION) 134
TABLE 69 GCC COUNTRIES: OTHER MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 70 MOLECULAR CYTOGENETICS CONSUMABLES MARKET, BY REGION,
2023–2030 (USD MILLION) 135
TABLE 71 NORTH AMERICA: MOLECULAR CYTOGENETICS CONSUMABLES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 72 EUROPE: MOLECULAR CYTOGENETICS CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 73 ASIA PACIFIC: MOLECULAR CYTOGENETICS CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 74 LATIN AMERICA: MOLECULAR CYTOGENETICS CONSUMABLES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 75 MIDDLE EAST: MOLECULAR CYTOGENETICS CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 137
TABLE 76 GCC COUNTRIES: MOLECULAR CYTOGENETICS CONSUMABLES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 77 MOLECULAR CYTOGENETICS INSTRUMENTS MARKET, BY REGION,
2023–2030 (USD MILLION) 138
TABLE 78 NORTH AMERICA: MOLECULAR CYTOGENETICS INSTRUMENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 79 EUROPE: MOLECULAR CYTOGENETICS INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 80 ASIA PACIFIC: MOLECULAR CYTOGENETICS INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 81 LATIN AMERICA: MOLECULAR CYTOGENETICS INSTRUMENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 82 MIDDLE EAST: MOLECULAR CYTOGENETICS INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 141
TABLE 83 GCC COUNTRIES: MOLECULAR CYTOGENETICS INSTRUMENTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 84 MOLECULAR CYTOGENETICS SOFTWARE & SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 142
TABLE 85 NORTH AMERICA: MOLECULAR CYTOGENETICS SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 86 EUROPE: MOLECULAR CYTOGENETICS SOFTWARE & SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 87 ASIA PACIFIC: MOLECULAR CYTOGENETICS SOFTWARE & SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 88 LATIN AMERICA: MOLECULAR CYTOGENETICS SOFTWARE & SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 89 MIDDLE EAST: MOLECULAR CYTOGENETICS SOFTWARE & SERVICES MARKET,
BY REGION, 2023–2030 (USD MILLION) 144
TABLE 90 GCC COUNTRIES: MOLECULAR CYTOGENETICS SOFTWARE & SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 91 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 146
TABLE 92 MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2023–2030 (USD MILLION) 147
TABLE 93 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 94 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN
SITU HYBRIDIZATION (FISH), BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 95 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN
SITU HYBRIDIZATION (FISH), BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 96 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 97 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN
SITU HYBRIDIZATION (FISH), BY REGION, 2023–2030 (USD MILLION) 149
TABLE 98 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 99 MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH), BY REGION, 2023–2030 (USD MILLION) 150
TABLE 100 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH), BY COUNTRY,
2023–2030 (USD MILLION) 151
TABLE 101 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH), BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 102 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH), BY COUNTRY,
2023–2030 (USD MILLION) 152
TABLE 103 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH), BY COUNTRY,
2023–2030 (USD MILLION) 152
TABLE 104 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH), BY REGION,
2023–2030 (USD MILLION) 153
TABLE 105 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH), BY COUNTRY,
2023–2030 (USD MILLION) 153
TABLE 106 MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY REGION, 2023–2030 (USD MILLION) 154
TABLE 107 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 108 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN
SITU HYBRIDIZATION (CISH), BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 109 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN
SITU HYBRIDIZATION (CISH), BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 110 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 111 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN
SITU HYBRIDIZATION (CISH), BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 112 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION (CISH), BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 113 MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES, BY REGION, 2023–2030 (USD MILLION) 157
TABLE 114 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 115 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES,
BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 116 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES,
BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 117 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 118 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES,
BY REGION, 2023–2030 (USD MILLION) 160
TABLE 119 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 120 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 162
TABLE 121 MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 163
TABLE 122 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 123 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS,
BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 124 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS,
BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 125 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 126 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 165
TABLE 127 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 128 MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY REGION,
2023–2030 (USD MILLION) 166
TABLE 129 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 130 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 131 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 132 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 133 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION) 169
TABLE 134 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 135 MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2023–2030 (USD MILLION) 170
TABLE 136 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 137 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 138 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 139 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 140 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2023–2030 (USD MILLION) 172
TABLE 141 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 142 MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 173
TABLE 143 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 144 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 145 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 146 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 147 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 176
TABLE 148 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 149 MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 178
TABLE 150 MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 179
TABLE 151 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 152 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 153 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 154 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 155 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 181
TABLE 156 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 157 MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 182
TABLE 158 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 159 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 160 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 161 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 162 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 185
TABLE 163 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 164 MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 186
TABLE 165 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 186
TABLE 166 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 187
TABLE 167 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 187
TABLE 168 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 188
TABLE 169 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 188
TABLE 170 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 188
TABLE 171 MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS, BY REGION,
2023–2030 (USD MILLION) 189
TABLE 172 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 173 EUROPE: MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 174 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 175 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 176 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS,
BY REGION, 2023–2030 (USD MILLION) 192
TABLE 177 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 192
TABLE 178 MOLECULAR CYTOGENETICS MARKET, BY REGION, 2023–2030 (USD MILLION) 194
TABLE 179 NORTH AMERICA: KEY MACROINDICATORS 195
TABLE 180 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 196
TABLE 181 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 197
TABLE 182 NORTH AMERICA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 197
TABLE 183 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 198
TABLE 184 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 198
TABLE 185 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 199
TABLE 186 US: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 200
TABLE 187 US: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 200
TABLE 188 US: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 201
TABLE 189 US: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 201
TABLE 190 US: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 202
TABLE 191 CANADA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 203
TABLE 192 CANADA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 203
TABLE 193 CANADA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 204
TABLE 194 CANADA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 204
TABLE 195 CANADA: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 205
TABLE 196 EUROPE: KEY MACROINDICATORS 206
TABLE 197 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 207
TABLE 198 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 207
TABLE 199 EUROPE: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 208
TABLE 200 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 208
TABLE 201 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 209
TABLE 202 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 209
TABLE 203 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 210
TABLE 204 GERMANY: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 205 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 211
TABLE 206 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 212
TABLE 207 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 212
TABLE 208 UK: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 213
TABLE 209 UK: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 214
TABLE 210 UK: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 214
TABLE 211 UK: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 215
TABLE 212 UK: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 215
TABLE 213 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 216
TABLE 214 FRANCE: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 216
TABLE 215 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 217
TABLE 216 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 217
TABLE 217 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 218
TABLE 218 ITALY: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 219
TABLE 219 ITALY: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 219
TABLE 220 ITALY: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 220
TABLE 221 ITALY: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 220
TABLE 222 ITALY: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 221
TABLE 223 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 222
TABLE 224 SPAIN: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 222
TABLE 225 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 223
TABLE 226 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 223
TABLE 227 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 224
TABLE 228 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 225
TABLE 229 REST OF EUROPE: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 225
TABLE 230 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 226
TABLE 231 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 226
TABLE 232 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 227
TABLE 233 ASIA PACIFIC: KEY MACROINDICATORS 228
TABLE 234 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 229
TABLE 235 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 230
TABLE 236 ASIA PACIFIC: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 230
TABLE 237 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 231
TABLE 238 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 231
TABLE 239 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 232
TABLE 240 CHINA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 233
TABLE 241 CHINA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 233
TABLE 242 CHINA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 234
TABLE 243 CHINA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 234
TABLE 244 CHINA: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 235
TABLE 245 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 236
TABLE 246 JAPAN: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 236
TABLE 247 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 237
TABLE 248 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 237
TABLE 249 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 238
TABLE 250 INDIA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 239
TABLE 251 INDIA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 239
TABLE 252 INDIA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 240
TABLE 253 INDIA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 240
TABLE 254 INDIA: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 241
TABLE 255 AUSTRALIA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 242
TABLE 256 AUSTRALIA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 242
TABLE 257 AUSTRALIA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 243
TABLE 258 AUSTRALIA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 243
TABLE 259 AUSTRALIA: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 244
TABLE 260 SOUTH KOREA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 245
TABLE 261 SOUTH KOREA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 245
TABLE 262 SOUTH KOREA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 246
TABLE 263 SOUTH KOREA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 246
TABLE 264 SOUTH KOREA: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 247
TABLE 265 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 248
TABLE 266 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 248
TABLE 267 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 249
TABLE 268 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 249
TABLE 269 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 250
TABLE 270 LATIN AMERICA: KEY MACROINDICATORS 251
TABLE 271 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 251
TABLE 272 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 252
TABLE 273 LATIN AMERICA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 252
TABLE 274 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 253
TABLE 275 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 253
TABLE 276 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 254
TABLE 277 BRAZIL: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 255
TABLE 278 BRAZIL: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 255
TABLE 279 BRAZIL: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 256
TABLE 280 BRAZIL: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 256
TABLE 281 BRAZIL: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 257
TABLE 282 MEXICO: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 258
TABLE 283 MEXICO: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 258
TABLE 284 MEXICO: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 259
TABLE 285 MEXICO: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 259
TABLE 286 MEXICO: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 260
TABLE 287 REST OF LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 261
TABLE 288 REST OF LATIN AMERICA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 261
TABLE 289 REST OF LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 262
TABLE 290 REST OF LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 262
TABLE 291 REST OF LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 263
TABLE 292 MIDDLE EAST: KEY MACROINDICATORS 264
TABLE 293 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY REGION,
2023–2030 (USD MILLION) 264
TABLE 294 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 265
TABLE 295 MIDDLE EAST: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 296 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 266
TABLE 297 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 266
TABLE 298 MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 267
TABLE 299 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 267
TABLE 300 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 268
TABLE 301 GCC COUNTRIES: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 268
TABLE 302 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 269
TABLE 303 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 269
TABLE 304 GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 270
TABLE 305 KINGDOM OF SAUDI ARABIA: MOLECULAR CYTOGENETICS MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 271
TABLE 306 KINGDOM OF SAUDI ARABIA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 271
TABLE 307 KINGDOM OF SAUDI ARABIA: MOLECULAR CYTOGENETICS MARKET,
BY TECHNIQUE, 2023–2030 (USD MILLION) 272
TABLE 308 KINGDOM OF SAUDI ARABIA: MOLECULAR CYTOGENETICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 272
TABLE 309 KINGDOM OF SAUDI ARABIA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 273
TABLE 310 UAE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 274
TABLE 311 UAE: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 274
TABLE 312 UAE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 275
TABLE 313 UAE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 275
TABLE 314 UAE: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 276
TABLE 315 REST OF GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 277
TABLE 316 REST OF GCC COUNTRIES: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 277
TABLE 317 REST OF GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 278
TABLE 318 REST OF GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 278
TABLE 319 REST OF GCC COUNTRIES: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 279
TABLE 320 REST OF MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 279
TABLE 321 REST OF MIDDLE EAST: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 280
TABLE 322 REST OF MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 280
TABLE 323 REST OF MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 281
TABLE 324 REST OF MIDDLE EAST: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023–2030 (USD MILLION) 281
TABLE 325 AFRICA: KEY MACROINDICATORS 283
TABLE 326 AFRICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 283
TABLE 327 AFRICA: MOLECULAR CYTOGENETICS KITS & REAGENTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 284
TABLE 328 AFRICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2023–2030 (USD MILLION) 284
TABLE 329 AFRICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 285
TABLE 330 AFRICA: MOLECULAR CYTOGENETICS MARKET, BY END USER,
2023–2030 (USD MILLION) 285
TABLE 331 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN MOLECULAR CYTOGENETICS MARKET, JANUARY 2022–SEPTEMBER 2025 286
TABLE 332 MOLECULAR CYTOGENETICS MARKET: DEGREE OF COMPETITION 290
TABLE 333 MOLECULAR CYTOGENETICS MARKET: REGION FOOTPRINT 296
TABLE 334 MOLECULAR CYTOGENETICS MARKET: PRODUCT & SERVICE FOOTPRINT 297
TABLE 335 MOLECULAR CYTOGENETICS MARKET: TECHNIQUE FOOTPRINT 298
TABLE 336 MOLECULAR CYTOGENETICS MARKET: APPLICATION FOOTPRINT 298
TABLE 337 MOLECULAR CYTOGENETICS MARKET: DETAILED LIST OF
KEY STARTUPS/SME PLAYERS 301
TABLE 338 MOLECULAR CYTOGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT & SERVICE AND REGION 302
TABLE 339 MOLECULAR CYTOGENETICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–SEPTEMBER 2025 303
TABLE 340 MOLECULAR CYTOGENETICS MARKET: DEALS, JANUARY 2022–SEPTEMBER 2025 304
TABLE 341 MOLECULAR CYTOGENETICS MARKET: EXPANSIONS,
JANUARY 2022–SEPTEMBER 2025 305
TABLE 342 MOLECULAR CYTOGENETICS MARKET: OTHER DEVELOPMENTS,
JANUARY 2022–SEPTEMBER 2025 305
TABLE 343 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 306
TABLE 344 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 307
TABLE 345 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–SEPTEMBER 2025 309
TABLE 346 DANAHER CORPORATION: COMPANY OVERVIEW 311
TABLE 347 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED 312
TABLE 348 DANAHER CORPORATION: PRODUCT LAUNCHES,
JANUARY 2022–SEPTEMBER 2025 314
TABLE 349 DANAHER CORPORATION: DEALS, JANUARY 2022–SEPTEMBER 2025 315
TABLE 350 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 317
TABLE 351 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED 318
TABLE 352 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES,
JANUARY 2022–SEPTEMBER 2025 320
TABLE 353 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 321
TABLE 354 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS,
JANUARY 2022–SEPTEMBER 2025 321
TABLE 355 ABBOTT: COMPANY OVERVIEW 323
TABLE 356 ABBOTT: PRODUCTS/SERVICES OFFERED 324
TABLE 357 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 326
TABLE 358 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 327
TABLE 359 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES,
JANUARY 2022–SEPTEMBER 2025 329
TABLE 360 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 329
TABLE 361 ILLUMINA, INC.: COMPANY OVERVIEW 331
TABLE 362 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED 332
TABLE 363 ILLUMINA, INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 333
TABLE 364 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 334
TABLE 365 REVVITY: COMPANY OVERVIEW 335
TABLE 366 REVVITY: PRODUCTS/SERVICES OFFERED 336
TABLE 367 REVVITY: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2025 337
TABLE 368 REVVITY: DEALS, JANUARY 2022–SEPTEMBER 2025 338
TABLE 369 PACBIO: COMPANY OVERVIEW 339
TABLE 370 PACBIO: PRODUCTS/SERVICES OFFERED 340
TABLE 371 PACBIO: DEALS, JANUARY 2022–SEPTEMBER 2025 341
TABLE 372 PACBIO: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 342
TABLE 373 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 343
TABLE 374 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 344
TABLE 375 BIO-TECHNE: COMPANY OVERVIEW 347
TABLE 376 BIO-TECHNE: PRODUCTS/SERVICES OFFERED 348
TABLE 377 BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2022–SEPTEMBER 2025 349
TABLE 378 BIO-TECHNE: DEALS, JANUARY 2022–SEPTEMBER 2025 350
TABLE 379 GENE DX, LLC: COMPANY OVERVIEW 351
TABLE 380 GENE DX, LLC: PRODUCTS/SERVICES OFFERED 352
TABLE 381 GENE DX, LLC: DEALS, JANUARY 2022–SEPTEMBER 2025 352
TABLE 382 INSIGHT MOLECULAR DIAGNOSTICS INC.: COMPANY OVERVIEW 353
TABLE 383 INISIGHT MOLECULAR DIAGNOSTICS INC.: PRODUCTS/SERVICES OFFERED 354
TABLE 384 BIOVIEW: COMPANY OVERVIEW 355
TABLE 385 BIOVIEW: PRODUCTS/SERVICES OFFERED 355
TABLE 386 OXFORD GENE TECHNOLOGY IP LIMITED: COMPANY OVERVIEW 357
TABLE 387 APPLIED SPECTRAL IMAGING: COMPANY OVERVIEW 358
TABLE 388 CYTOTEST INC.: COMPANY OVERVIEW 359
TABLE 389 KROMATID: COMPANY OVERVIEW 360
TABLE 390 GENIAL GENETIC SOLUTIONS LTD.: COMPANY OVERVIEW 361
TABLE 391 CYTOGNOMIX INC.: COMPANY OVERVIEW 362
TABLE 392 METASYSTEMS: COMPANY OVERVIEW 363
TABLE 393 SCIGENE CORPORATION: COMPANY OVERVIEW 364
TABLE 394 BIOMODAL: COMPANY OVERVIEW 365
TABLE 395 BIOCARE MEDICAL, LLC: COMPANY OVERVIEW 366
TABLE 396 BIODOT: COMPANY OVERVIEW 367
TABLE 397 ONCODNA: COMPANY OVERVIEW 368
LIST OF FIGURES
FIGURE 1 MOLECULAR CYTOGENETICS MARKET SEGMENTATION & REGIONAL SCOPE 35
FIGURE 2 MOLECULAR CYTOGENETICS MARKET: YEARS CONSIDERED 36
FIGURE 3 MOLECULAR CYTOGENETICS MARKET: RESEARCH DESIGN 38
FIGURE 4 MOLECULAR CYTOGENETICS MARKET: BREAKDOWN OF PRIMARIES
(SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 40
FIGURE 5 MOLECULAR CYTOGENETICS MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2024 41
FIGURE 6 MOLECULAR CYTOGENETICS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH), 2024 42
FIGURE 7 REVENUE ANALYSIS: ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA
ROCHE LTD. (2024) 42
FIGURE 8 MOLECULAR CYTOGENETICS MARKET: INSIGHTS FROM KEY PRIMARIES 44
FIGURE 9 MOLECULAR CYTOGENETICS MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 45
FIGURE 10 MOLECULAR CYTOGENETICS MARKET: CAGR PROJECTIONS 46
FIGURE 11 MOLECULAR CYTOGENETICS MARKET: DATA TRIANGULATION 48
FIGURE 12 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE,
2025 VS. 2030 (USD MILLION) 51
FIGURE 13 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE,
2025 VS. 2030 (USD MILLION) 52
FIGURE 14 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION,
2025 VS. 2030 (USD MILLION) 52
FIGURE 15 MOLECULAR CYTOGENETICS MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 53
FIGURE 16 MOLECULAR CYTOGENETICS MARKET: REGIONAL ANALYSIS 54
FIGURE 17 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST (USD MILLION) 57
FIGURE 18 US AND GENETIC DISORDERS COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024 58
FIGURE 19 CLINICAL & DIAGNOSTIC LABORATORIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 59
FIGURE 20 ASIA PACIFIC TO BE FASTEST-GROWING REGION IN GLOBAL MOLECULAR CYTOGENETICS MARKET DURING STUDY PERIOD 60
FIGURE 21 MOLECULAR CYTOGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64
FIGURE 22 NUMBER OF CANCER CASES IN US, 2019–2024 67
FIGURE 23 MOLECULAR CYTOGENETICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 71
FIGURE 24 AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2024 (USD) 75
FIGURE 25 AVERAGE SELLING PRICE OF KITS, BY KEY PLAYER, 2024 (USD) 75
FIGURE 26 AVERAGE SELLING PRICE OF REAGENTS, BY KEY PLAYER, 2024 (USD) 76
FIGURE 27 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD) 77
FIGURE 28 AVERAGE SELLING PRICE OF KITS, BY REGION, 2024 (USD) 78
FIGURE 29 AVERAGE SELLING PRICE OF REAGENTS, BY REGION, 2024 (USD) 78
FIGURE 30 PATENT APPLICATIONS IN MOLECULAR CYTOGENETICS MARKET,
JANUARY 2014–DECEMBER 2024 80
FIGURE 31 MOLECULAR CYTOGENETICS MARKET: VALUE CHAIN ANALYSIS 84
FIGURE 32 MOLECULAR CYTOGENETICS MARKET: ECOSYSTEM ANALYSIS 87
FIGURE 33 MOLECULAR CYTOGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS 90
FIGURE 34 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS,
BY PRODUCT & SERVICE 92
FIGURE 35 KEY BUYING CRITERIA, BY END USER 93
FIGURE 36 US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 96
FIGURE 37 CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 97
FIGURE 38 EUROPE: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 98
FIGURE 39 JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 99
FIGURE 40 INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 101
FIGURE 41 BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 102
FIGURE 42 FUNDING AND NUMBER OF DEALS IN MOLECULAR CYTOGENETICS MARKET, 2022–2025 (USD MILLION) 106
FIGURE 43 IMPACT OF AI/GEN AI ON MOLECULAR CYTOGENETICS MARKET 107
FIGURE 44 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET SNAPSHOT 196
FIGURE 45 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET SNAPSHOT 229
FIGURE 46 REVENUE ANALYSIS OF KEY PLAYERS IN MOLECULAR CYTOGENETICS MARKET, 2020–2024 (USD MILLION) 289
FIGURE 47 MARKET SHARE ANALYSIS OF KEY PLAYERS IN MOLECULAR
CYTOGENETICS MARKET (2024) 290
FIGURE 48 EV/EBITDA OF KEY VENDORS 292
FIGURE 49 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK
BETA OF KEY VENDORS 292
FIGURE 50 MOLECULAR CYTOGENETICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 293
FIGURE 51 MOLECULAR CYTOGENETICS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 295
FIGURE 52 MOLECULAR CYTOGENETICS MARKET: COMPANY FOOTPRINT 296
FIGURE 53 MOLECULAR CYTOGENETICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 300
FIGURE 54 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 307
FIGURE 55 DANAHER CORPORATION: COMPANY SNAPSHOT 312
FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 318
FIGURE 57 ABBOTT: COMPANY SNAPSHOT 324
FIGURE 58 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 327
FIGURE 59 ILLUMINA, INC.: COMPANY SNAPSHOT 332
FIGURE 60 REVVITY: COMPANY SNAPSHOT 336
FIGURE 61 PACBIO: COMPANY SNAPSHOT 340
FIGURE 62 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 344
FIGURE 63 BIO-TECHNE: COMPANY SNAPSHOT 348
FIGURE 64 GENE DX, LLC: COMPANY SNAPSHOT 351
FIGURE 65 INSIGHT MOLECULAR DIAGNOSTICS INC.: COMPANY SNAPSHOT 353
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11